Genomic alterations underlying spinal metastases in pediatric H3K27M-mutant pineal parenchymal tumor of intermediate differentiation: case report

Restricted access

Pediatric midline tumors are devastating high-grade lesions with a dismal prognosis and no curative surgical options. Here, the authors report the clinical presentation, surgical management, whole-exome sequencing (WES), and clonality analysis of a patient with a radically resected H3K27M-mutant pineal parenchymal tumor (PPT) and spine metastases consistent with PPT of intermediate differentiation (PPTID). They identified somatic mutations in H3F3A (H3K27M), FGFR1, and NF1 both in the original PPT and in the PPTID metastases. They also found 12q amplification containing CDK4/MDM2 and chromosome 17 loss of heterozygosity overlapping with NF1 that resulted in biallelic NF1 loss. They noted a hypermutated phenotype with increased C>T transitions within the PPTID metastases and 2p amplification overlapping with the MYCN locus. Clonality analysis detected three founder clones maintained during progression and metastasis. Tumor clones present within the PPTID metastases but not the pineal midline tumor harbored mutations in APC and TIMP2.

While the majority of H3K27M mutations are found in pediatric midline gliomas, it is increasingly recognized that this mutation is present in a wider range of lesions with a varied morphological appearance. The present case appears to be the first description of H3K27M mutation in PPTID. Somatic mutations in H3F3A, FGFR1, and NF1 have been suggested to be driver mutations in pediatric midline gliomas. Their clonality and presence in over 80% of tumor cells in our patient’s PPTID are consistent with similarly crucial roles in early tumorigenesis, with progression mediated by copy number variations and chromosomal aberrations involving known oncogenes and tumor suppressors. The roles of APC and TIMP2 mutations in progression and metastasis remain to be investigated.

ABBREVIATIONS CNV = copy number variation; DIPG = diffuse intrinsic pontine glioma; GBM = glioblastoma; LOH = loss of heterozygosity; PPT = pineal parenchymal tumor; PPTID = PPT of intermediate differentiation; VAF = variant allele frequency; WES = whole-exome sequencing; WHO = World Health Organization.

Supplementary Materials

  • Supplemental Tables 1 to 3 (PDF 703 KB)
Article Information

Contributor Notes

Correspondence Kristopher T. Kahle: Yale School of Medicine, New Haven, CT. kristopher.kahle@yale.edu.INCLUDE WHEN CITING Published online October 25, 2019; DOI: 10.3171/2019.8.PEDS18664.

E.I.F. and E.Z.E.O. share first authorship, and A.J.K. and C.S.H. share second authorship of this paper.

Disclosures The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper.
Headings
TrendMD
Metrics

Metrics

All Time Past Year Past 30 Days
Abstract Views 182 182 182
Full Text Views 66 66 66
PDF Downloads 40 40 40
EPUB Downloads 0 0 0
PubMed
Google Scholar